Connect Sign In
ARUP and Medicover have partnered to provide a new companion diagnostic test to European Union patients. The test helps identify individuals eligible for a new gene therapy for severe hemophilia A.
A panel discussion at the Utah Life Sciences Summit explored how the FDA’s proposed rule to further regulate laboratory-developed tests could slow advances in diagnostic medicine.
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.
ARUP experts in molecular pathology will present at, participate in, and be available to attendees during the upcoming Association for Molecular Pathology (AMP) Meeting and Expo in Salt Lake City.
The Association for the Advancement of Blood and Biotherapies recommends that providers use a restrictive transfusion strategy to reduce unnecessary transfusions and the risk of adverse events.
The newest edition highlights innovations that keep ARUP at the forefront of toxicology testing. Also featured: ARUP’s expanded capacity for cytogenetics testing.
A platform clients use to reduce testing waste, lower cost per test, and improve patient safety has won the prestigious Choosing Wisely Champion Award from the American Society for Clinical Pathology.
New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
A novel event organized by ARUP’s Patent Committee aimed to highlight creative solutions that may not lead to patents but still advance laboratory medicine and improve patient care.
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
ARUP’s Clinical Trials and PharmaDx groups supported Blueprint Medicines’ clinical trials that led to FDA approval for AYVAKIT® (avapritinib), a new treatment for indolent systemic mastocytosis.
ARUP and Gestalt Diagnostics announced a partnership under which ARUP will adopt Gestalt’s PathFlow® platform as a foundation for future digital pathology initiatives.
